A Randomized Phase II Study of Erdafitinib Versus Investigator Choice of Intravesicular Chemotherapy in Subjects Who Received Bacillus Calmette-Gu�rin BCG and Progressed or Recurred With High Risk Non-Muscle-Invasive Bladder Cancer NMIBC and FGFR Mutations or Fusions
Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative with Evident Efficacy in Patients with Muscle Invasive Bladder Cancer